1. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. (3rd July 2014) Authors: Lin, Thet Thet; Norris, Kevin; Heppel, Nicole H.; Pratt, Guy; Allan, James M.; Allsup, David J.; Bailey, James; Cawkwell, Lynn; Hills, Robert; Grimstead, Julia W.; Jones, Rhiannon E.; Britt‐Compton, Bethan; Fegan, Chris; Baird, Duncan M.; Pepper, Chris Journal: British journal of haematology Issue: Volume 167:Number 2(2014:Oct.) Page Start: 214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Telomere length is a critical determinant for survival in multiple myeloma. (24th March 2017) Authors: Hyatt, Sam; Jones, Rhiannon E.; Heppel, Nicole H.; Grimstead, Julia W.; Fegan, Chris; Jackson, Graham H.; Hills, Robert; Allan, James M.; Pratt, Guy; Pepper, Chris; Baird, Duncan M. Journal: British journal of haematology Issue: Volume 178:Number 1(2017) Page Start: 94 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Telomere length is an independent prognostic marker in MDS but not in de novo AML. (9th May 2017) Authors: Williams, Jenna; Heppel, Nicole H.; Britt‐Compton, Bethan; Grimstead, Julia W.; Jones, Rhiannon E.; Tauro, Sudhir; Bowen, David T.; Knapper, Steven; Groves, Michael; Hills, Robert K.; Pepper, Chris; Baird, Duncan M.; Fegan, Chris Journal: British journal of haematology Issue: Volume 178:Number 2(2017) Page Start: 240 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗